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Abstract
Background: Cross-immunity between seasonal and pandemic A/H1N1 influenza viruses remains uncertain. In particular,
the extent that previous infection or vaccination by seasonal A/H1N1 viruses can elicit protective immunity against
pandemic A/H1N1 is unclear.
Methodology/Principal Findings: Neutralizing titers against seasonal A/H1N1 (A/Brisbane/59/2007) and against pandemic
A/H1N1 (A/California/04/2009) were measured using an HIV-1-based pseudovirus neutralization assay. Using this highly
sensitive assay, we found that a large fraction of subjects who had never been exposed to pandemic A/H1N1 express high
levels of pandemic A/H1N1 neutralizing titers. A significant correlation was seen between neutralization of pandemic A/
H1N1 and neutralization of a standard seasonal A/H1N1 strain. Significantly higher pandemic A/H1N1 neutralizing titers
were measured in subjects who had received vaccination against seasonal influenza in 2008–2009. Higher pandemic
neutralizing titers were also measured in subjects over 60 years of age.
Conclusions/Significance: Our findings reveal that the extent of protective cross-immunity between seasonal and
pandemic A/H1N1 influenza viruses may be more important than previously estimated. This cross-immunity could provide a
possible explanation of the relatively mild profile of the recent influenza pandemic.
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Introduction
The influenza A/H1N1 virus of swine origin, first isolated in
April 2009 in Mexico and the United States, has now been
spreading worldwide, causing the first influenza pandemic in more
than 40 years [1,2,3]. Although this virus generally causes only
mild clinical symptoms, a number of severe cases have been
described, prompting rapid development of specific vaccine
preparations for mass vaccination [4,5,6,7]. In this context,
however, the extent that preexisting immunity to seasonal
influenza viruses can provide cross-protection against pandemic
A/H1N1 remains uncertain. Using a highly sensitive pseudovirus
neutralization (PN) assay, we have examined the ability of sera
from 107 subjects with no history of exposure to pandemic A/
H1N1 to cross-neutralize this new influenza strain. We correlated
these cross-neutralization titers with neutralization of a standard
seasonal A/H1N1 strain, and evaluated the impact of the subject’s
age and history of recent seasonal influenza vaccination on cross-
neutralization.
Results
None of the 107 subjects had reported recent symptoms
evocative of influenza infection in the weeks preceding serum
sampling, a period during which the pandemic A/H1N1
influenza had barely reached epidemic levels (181 cases/
100,000 persons) in France [8]. The median age of the subjects
was 44 years (range 20–90 years), 75/107 were female, and 54/
107 reported vaccination by trivalent seasonal influenza vaccine
during the 2008/2009 epidemic season. In order to obtain a
batch of positive control sera expressing high titers of neutralizing
antibodies against the pandemic strain, a group of 10 subjects
were vaccinated against pandemic A/H1N1 by a single injection
of an adjuvanted, split virus vaccine preparation containing
3.75 mg of viral hemagglutinin (PandemrixH, Glaxo SmithKline).
Serum from these 10 subjects was collected before and 3–4 weeks
after this inoculation and tested for cross-neutralization of
pandemic and seasonal A/H1N1, alongside the 107 other serum
samples.
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analysis on all tested samples, yielding satisfactory intraclass
correlation coefficients (ICC) of 0.840 (95%CI 0.774 to 0.888) and
0.846 (95%CI 0.782 to 0.892) for the pandemic and seasonal
viruses, respectively. The specificity of the assay was validated by
comparing neutralization titers of pre- and post-pandemic A/
H1N1 vaccination serum samples from the 10 subjects described
above. The results of this analysis are shown on table 1.
Vaccination against the pandemic strain increased pandemic A/
H1N1 neutralizing titers in the PN assay by a geometric mean of
12.8-fold (95%CI 4.9 to 33.5, p,0.0001 vs baseline), while
seasonal vaccinal Brisbane A/H1N1 neutralizing titers only
increased by 1.2-fold (95%CI 0.31 to 4.5). As a control, the same
pairs of samples were also tested using a standard hemagglutina-
tion inhibition (HI) assay measuring antibodies to the pandemic
A/H1N1 virus, which showed clear but relatively modest increases
in antibody titers, when compared to the increases measured by
the PN assay. Using the HI assay, baseline titers were low (titer
,40 in 9/10 samples) and increased following vaccination in all
subjects, but only 7/10 post-vaccination sera had a titer $80
(Table 1). A significant correlation, however, was seen between the
PN and HI titers in sera from subjects having received the
pandemic A/H1N1 vaccine (Spearman rs=0.96, 95%CI 0.85 to
0.99, p,0.0001; data not shown).
The range of pandemic A/H1N1 neutralizing antibody titers by
PN assay in subjects who had no known exposure to this virus was
remarkably wide, and often reached surprisingly high levels. Only
9 sera titrated ,100 while 43 titrated between 100 and 500, 45
titrated between 500 and 2500, and 10 sera titrated .2500,
including two sera with titers .20,000. A comparable range of
neutralizing titers was observed against the seasonal Brisbane A/
H1N1 strain. Moreover, as illustrated on figure 1, a significant
correlation was observed between the neutralizing titers against
the two strains (Spearman rs=0.50, 95%CI 0.34 to 0.63,
p,0.0001). This finding strongly suggests that previous exposure
to seasonal influenza viruses and/or previous seasonal influenza
vaccination had conferred some level of protective immunity
against the new pandemic A/H1N1 strain in many of the study
subjects. We therefore compared the pandemic A/H1N1 and
seasonal Brisbane vaccinal A/H1N1 neutralizing titers in sera
from subjects having reported inoculation by a seasonal trivalent
influenza vaccine during the 2008–2009 epidemic season to titers
measured in sera from subjects who did not report such
vaccination. As shown on figure 2, this comparison revealed
significantly higher neutralizing titers to both the seasonal and
pandemic strains in vaccinated subjects (p=0.002 for both
comparisons), indicating that in subjects who had never been
exposed to pandemic A/H1N1 antigens, vaccination against
seasonal influenza during the previous year had elicited antibodies
with the ability to cross-neutralize the pandemic strain. We also
examined the effect of age on the presence of cross-neutralizing
antibodies to pandemic A/H1N1 in the same population of
subjects. As shown on figure 3, sera from patients older than 60
had significantly higher neutralizing titers to the pandemic virus
than younger patients, but no difference was seen when the two
age classes were compared for neutralizing titers against the
seasonal virus.
Discussion
Based on a highly sensitive pseudovirus neutralization assay, we
found that a large proportion of sera from a panel of subjects with
no previous exposure to the recently emerged pandemic A/H1N1
influenza strain expressed high titers of neutralizing antibodies
against this new virus. Furthermore, our data show that these
neutralizing titers correlate significantly with neutralizing titers
against a seasonal A/H1N1 virus measured in parallel, and that
the pandemic A/H1N1 neutralizing titer is significantly higher in
subjects who had been incoculated by a seasonal trivalent
influenza vaccine during the previous year. These data are in
apparent contradiction with the conclusions of a retrospective
study reported by Hancock et al. [9], where only minor changes in
pandemic A/H1N1 neutralizing titers were measured following
seasonal influenza vaccination. We believe that the difference
between our observations and those of Hancock et al. owes largely
to the sensitivity and reproducibility of the PN assay used in our
study, which allows measurement of neutralizing titers over a wide
range of values and with high discrimination between titers of
different levels.
Our findings are in line with several reports suggesting that
some level of A/H1N1 cross-neutralization could be induced by
Table 1. Changes in neutralizing and HI titers after pandemic A/H1N1 vaccination.








#1 10 35.7 38 31.4 ,40 40
#2 43 0.41 166 14.8 ,40 160
#3 200 1.62 461 9.8 ,40 160
#4 316 2.03 425 21.7 80 320
#5 387 0.79 111 22.0 ,40 160
#6 502 3.09 409 5.4 ,40 80
#7 596 0.65 265 90.0 ,40 320
#8 625 0.30 409 2.9 ,40 40
#9 1505 0.29 223 3.2 ,40 40
#10 1640 0.63 965 12.3 ,40 320
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the safety and immunogenicity of vaccine preparations against
pandemic A/H1N1, high titers of HI antibodies were seen in
subjects before vaccination [10,11,12], and at least one of these
studies provided indications of higher HI or neutralizing titers in
subjects with a history of recent vaccination against seasonal
influenza A [12]. Second, a recent report revealed that priming
with a seasonal A/H1N1 inoculation before pandemic A/H1N1
vaccination could enhance protection of ferrets against pandemic
H1N1 [13]. Third, strong evidence exists that several epitopes in
HA could promote cross-immunity between distant strains of
influenza A viruses [14,15] and that subjects with previous
immunity to seasonal A/H1N1 may delelop milder form of
pandemic A/H1N1 infection [16]. Taken together, these and our
results strongly suggest that some extent of cross-protection against
pandemic A/H1N1 may exist in a proportion of subjects in the
general population, and that prior vaccination against seasonal A/
H1N1 explains, at least in part, this cross-immunity.
Several factors could explain the high levels of cross-immunity
observed in our study. The particularly strong cross-immunity seen
in subjects older than 60 (Fig 3) is noteworthy. It is in agreement
with a recent study evaluating HI and microneutralization titers in
sera obtained in 2008 [17] and with with a study examining HI
titers in 2009 sera [18]. Interestingly, we observe that the higher
pandemic A/H1N1 neutralizing titers measured in these subjects
are not accompanied by higher seasonal A/H1N1 titers,
suggesting that they may have had past exposure to A/H1N1
variants that share more antigenic similarity to the new pandemic
A/H1N1 virus than to recently circulating seasonal A/H1N1
strains. Nonetheless, since high pandemic neutralizing tirers were
also measured in younger subjects and particularly in subjects
having received seasonal A/H1N1 vaccination during the 2008–
2009 season, our data indicate that the observed cross-immunity
can also be partly explained by immunity against seasonal A/
H1N1 strains, in spite of the wide genetic distance between recent
A/H1N1 influenza strains and the new pandemic strain. Of note,
while vaccination against seasonal A/H1N1 was significantly
associated with higher pandemic neutralizing titers, there was no
increase in seasonal neutralizing titers in the 10 control subjects
who were vaccinated against pandemic A/H1N1. The mecha-
nisms underlying this ‘‘asymmetric’’ cross-immunity have yet to be
understood.
Figure 1. Correlation between pandemic A/H1N1 and seasonal
A/H1N1 neutralizing titers. Neutralizing titers are expressed as the
log10 of the geometric mean of titers calculated as described in
Materials and Methods in two independent experiments. Linear
regression curve (continuous line) and 95%CI (dotted line) are
presented. The correlation coefficient and P value were calculated by
Spearman test.
doi:10.1371/journal.pone.0011036.g001
Figure 2. Comparison of pandemic A/H1N1 neutralizing titers
in subjects vaccinated or not against seasonal influenza during
the 2008–2009 epidemic season. Box and whiskers plots present
the median, first and third quartile of the distribution (box) and outer
whiskers extend the whole range of data. P values are from a Wilcoxon
rank sum test.
doi:10.1371/journal.pone.0011036.g002
Figure 3. Comparison of pandemic A/H1N1 neutralizing titers
in subjects according to age. Symbols and P values are the same as
those on figure 2.
doi:10.1371/journal.pone.0011036.g003
Pandemic A/H1N1 Neutralization
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had any impact on the relatively mild profile of the current
pandemic remains to be determined, and at this stage, our results
do not invalidate the clinical and epidemiological utility of mass
vaccination against pandemic A/H1N1 influenza virus. In fact,
the cross-immunity described here could explain, at least in part,
the strong immunological response to a single dose of pandemic
A/H1N1 vaccine in adults.
Materials and Methods
Serum samples from 107 subjects were obtained between Aug
18 and Oct 10, 2009 from primary care personnel and patients at
Ho ˆpital Saint Louis, Paris, France. Written informed consent was
obtained for all patients, and the study was approved by the Paris
Saint-Louis ethical committee.
The pseudovirus neutralization assay used in this study is based
on infectivity of pseudotyped HIV-1 particles expressing influenza
HA proteins. Briefly, subconfluent monolayers of human 293-T
cells in 6-well plates were co-transfected with 0.7 mg of the HIV-1
pNL4-3-DENV-LucR vector and 0.5 mg of the pVITRO2-blasti-
mcs-tat plasmid, expressing the influenza HA protein either from a
vaccinal strain of seasonal A/H1N1 (A/Brisbane/59/2007) or
from pandemic A/H1N1 (A/California/04/2009), and grown in
the presence of 5 mU/mL of soluble Clostridium perfringens
neuraminidase. After 48 hours, the pseudovirus-containing super-
natants were harvested and volumes of supernatant expressing an
infectious titer of 10
4 RLU (Relative Light Unit) were incubated
with twofold dilutions of decomplemented test serum (starting
dilution 1:20) for 1 hour at 37uC. Subsequently, 200 mL of virus-
antibody mixture were transferred to MDCK-SIAT1 target cell
cultures in quadruplicate in 96-well plates. The inhibitory effect of
serum on pseudovirus infectivity was measured 48 h later by fitting
the percent inhibition of RLU values to a sigmoid dose-response
curve with variable slope, using the GraphPad Prism 4.0b software.
The neutralizing titer was defined as the reciprocal of the serum
dilution required to reduce viral infectivity by 50% and expressed
as the geometric mean from two independent experiments.
Titration of antibodies to pandemic A/H1N1 by hemaggluti-
nation inhibition (HI) was performed by a standard assay using
human group O erythrocytes and non-inactivated pandemic A/
H1N1 virus.
Correlations and comparisons between neutralizing titers were
done based on the log10 values of the titers. Correlations between
neutralizing titers were examined by calculating the Spearman
correlation coefficient; comparisons of neutralizing titers before
and after pandemic A/H1N1 vaccination were done using the
Wilcoxon signed rank-sum test; comparison of neutralizing titers
between subject groups were performed using the Wilcoxon rank-
sum test.
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